on Leon-nanodrugs GmbH
LEON's FR-JET Technology Validated for Advanced Nanoparticle Manufacturing
leon-nanodrugs GmbH, a German Pharmatech company, has successfully concluded a feasibility study in collaboration with Evonik Canada Inc. The study confirmed the performance of LEON’s FR-JET technology for manufacturing nanoparticles used in drug delivery. This validation highlights FR-JET's efficiency, precision, and consistency in producing high-quality nanoparticles.
The study involved creating various drug-loaded and placebo nanoparticles using lipid and polymer-based systems. It demonstrated FR-JET's versatility and scalability, beneficial for both research and commercial production. This aligns with the growing demand for versatile manufacturing platforms to support the diversity of active pharmaceutical ingredients and delivery systems.
The results pave the way for advancements in drug delivery, especially crucial for the progress of cell and gene therapies. Dr. Setu Kasera, LEON's Chief Scientific Officer, expressed enthusiasm about the technology's validation, noting its potential to enhance drug performance and streamline production processes.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Leon-nanodrugs GmbH news